Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia

By sjmartinez • October 7, 2023

Gaut D, Oliai C, Boiarsky J, Zhang S, Salhotra A, Azenkot T, Kennedy VE, Khanna V, Olmedo Gutierrez K, Shukla N, Moskoff B, Park G, Afkhami M, Patel A, Jeyakumar D, Mannis G, Logan AC, Jonas BA, Schiller G. Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia. Leuk Lymphoma. 2023 Oct 6:1-9. doi: 10.1080/10428194.2023.2264426. Epub ahead of print. PMID: 37801340.

Tags: Acute myeloid leukemia, allogeneic hematopoietic stem cell transplantation, consolidation chemotherapy, fellows, General Internal Medicine, Hematology/Oncology, measurable residual disease, Publications, Resident

Sequencing of anti-CD19 therapies in the management of diffuse large B-cell lymphoma

Lownik J, Boiarsky J, Birhiray R, Merchant A, Mead M. Sequencing of anti-CD19 therapies in the management of diffuse large B-cell lymphoma. Clin Cancer Res.[...]

Outpatient hospitalist-run procedure service bridges the gap in oncology care

Ghanem G, Tsai HHC, Durant C, Feigenbaum GS, Glaeser AM. Outpatient hospitalist-run procedure service bridges the gap in oncology care. Transfus Apher Sci. 2024 Apr[...]

Statewide Survey of Primary Care and Subspecialty Providers on Hepatocellular Carcinoma Risk-Stratification and Surveillance Practices

Moon AM, Swier RM, Lane LM, Barritt AS 4th, Sanoff HK, Olshan AF, Wheeler SB, Ioannou GN, Kim NJ, Hagan S, Vutien P, Benefield T,[...]